Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intoleran Quatrase is a multi-enzyme digestive supplement designed to aid in the breakdown of fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs). It contains a specific blend of four enzymes: lactase, xylose isomerase, alpha-galactosidase, and invertase. These enzymes target the digestion of lactose, fructose, galactans, and sucrose, respectively. Developed by the company Intoleran, the product is being evaluated in clinical research, including a randomized cross-over controlled feeding trial sponsored by Monash University, to determine its efficacy in maintaining symptom control in adults with irritable bowel syndrome (IBS) who are following a low FODMAP diet. It is formulated as an oral capsule and is certified as Low FODMAP by Monash University.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Intoleran Quatrase.